MonotherApy of Low-does TicagrElor After Percutaneous Coronary Intervention
Status:
Not yet recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
The MATE study is a randomized, multicenter, open-label, investigator-initiated clinical
trial aimed to evaluate efficacy and safety of sequential single antiplatelet therapy of
low-dose Ticagrelor and clopidogrel in patients with acute coronary syndrome (ACS) and high
bleeding risk after coronary intervention. Eligible patients will be randomized at 1:1 ratio
after PCI, into receiving standard-dose ticagrelor DAPT (SD.T) for 12months , or low-dose
ticagrelor DAPT for only 1 month, followed by 5 months of low-dose ticagrelor monotherapy,
and further de-escalated monotherapy of clopidogrel for another 6 months(LD.T).
The current study is to observe whether the low-does potent P2Y12 inhibitor can largely
reduce clinical-relevant bleeding versus dual antiplatelet therapy, while keep non-inferior
on thrombotic risk in ACS patients with high bleeding risk.
Phase:
Phase 4
Details
Lead Sponsor:
Second Affiliated Hospital, School of Medicine, Zhejiang University